Equine IL-36 Receptor Antagonist (IL-36RA) Recombinant Protein

The Equine IL-36 Receptor Antagonist yeast-derived recombinant protein is not tagged and is naturally endotoxin-free. The purity is greater than 98% as visualized by SDS-PAGE analysis. Equine IL-36 Receptor Antagonist applications are for cell culture, ELISA standard, and Western Blot Control. Equine IL-36 Receptor Antagonist yeast-derived recombinant protein can be purchased in multiple sizes. Equine IL-36 Receptor Antagonist Specifications: (Molecular Weight: 17.0 kDa) (Amino Acid Sequence: VLSGALCFRM KDAALKVLYL HDNQLLAGGL HTGKVMKGEE ISVVPNRFLD AKLSPVILGV QGGSQCLSCG TEQEPTLKLE PVNIMELYLG AKEYKSFTFY RRDTGLTSSF ESAAYPGWFL CTVPEADQPL RLTQLPEDAS GDDPITDFYF QQCD (154) ) (Gene ID: 100065154) . For research use only.

Product Specifications

Background

Interleukin 36, or IL-36, is a group of cytokines in the IL-1 family with pro-inflammatory effects. There are four members of the IL-36 family which bind to the IL-36 receptor (IL1RL2/IL-1Rrp2/IL-36 receptor dimer) with varying affinities. IL36A, IL36B, and IL36G are IL-36 receptor agonists. IL36RA is an IL-36 receptor antagonist, inhibiting IL-36R signaling. The agonists are known to activate NF-κB and mitogen-activated protein kinases to induce various proinflammatory mediators. Binding of the IL-36R agonists to IL-1Rp2 recruits IL-1RAcP, activating the signaling pathway. IL-36Ra binds to IL-36R, preventing the recruitment of IL-1RAcP. IL-36 has been found to activate T cell proliferation and release of IL-2. Due to their predominant expression in epithelial tissues, IL-36 cytokines are believed to play a significant role in the pathogenesis of skin diseases, especially that of psoriasis. IL-36 has also been linked to psoriatic arthritis, systemic lupus erythematosus, inflammatory bowel disease, ulcerative colitis, Crohn's disease, and Sjoegren's syndrome. IL-36 is expressed by many cells types, most predominately keratinocytes, respiratory epithelium, various nervous tissue, and monocytes.